Navigation Links
XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
Date:5/13/2008

slide presentation can be accessed via the investor relations section of the Company's website at http://investor.xtentinc.com/events.cfm. Please dial in or access the website five to 10 minutes prior to the beginning of the call. If you do dial in, please also view the slides via the webcast. The webcast will be archived on the website for a minimum of three months, and can be accessed at the investor relations portion of the company's website at http://investor.xtentinc.com.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the timing of the release of its clinical trial data. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's annual report on Form 10-K for the year ended December 31, 2007. This ann
'/>"/>

SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
2. XTENT Announces First Quarter 2008 Financial Results
3. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
4. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
5. XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
6. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
7. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
8. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
9. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
10. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... JERUSALEM , June 2, 2015 ... http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... a scientific abstract summarizing studies performed with ORMD-0801, its ... will be presented at the poster sessions in the ... 2015 in Boston . The poster ...
(Date:6/2/2015)... June 2, 2015  PROMETRIKA, LLC, a full-service ... with the addition of pharmacovigilance services for clinical ... in safety data collection and reporting, as our ... professionals, and expert physicians, each with more than ... and monitoring of safety trends. ...
(Date:6/2/2015)... VALLEY FORGE, Pa. , June 2, 2015 /PRNewswire/ ... plans to  build three new distribution centers in ... MN ; and Newburgh, NY ... strengthening the company,s ability to improve product access, increase ... Today,s announcement is part of the company,s ongoing ...
Breaking Medicine Technology:Oramed to Present at the American Diabetes Association 75th Scientific Sessions 2Oramed to Present at the American Diabetes Association 75th Scientific Sessions 3Oramed to Present at the American Diabetes Association 75th Scientific Sessions 4PROMETRIKA Announces the Availability of Pharmacovigilance Services 2AmerisourceBergen to Build Three New Distribution Centers 2
(Date:6/2/2015)... June 02, 2015 The Down Syndrome ... Potter from the hit show Glee as the keynote ... Walk in Pleasant Prairie, WI. The event aims to ... in Racine, Kenosha, and Walworth counties. ... join us for this important event," says Dawn Nuoffer, ...
(Date:6/2/2015)... York, NY (PRWEB) June 02, 2015 ... Profemur hip replacement lawsuit ( http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) is ... County. According to court documents, opening statements were ... asserting that laser etchings on the Profemur hip ... fracture, causing it to snap just three years ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Tronics, a ... deploying its growth strategy to benefit from the significant ... Yole Développement’s May 2015 Status of the MEMS Industry ... sharply and reach $6.6B in 2020,” says Frederic Breussin, ... Développement . , The analyst adds that “although the ...
(Date:6/2/2015)... ANT Wireless, proven innovator in ultra-low power ... new products implementing the ANT+ Fitness Equipment Control (FE-C) ... in their bike trainer products, built to create an ... the FE-C device profile in its Vortex Smart and ... indoor training software, while Kinomap has added FE-C support ...
(Date:6/2/2015)... Acara Partners has seen a spike in demand for ... as is now required by recent Google search algorithm changes. ... several new clients in the medical aesthetics vertical, are anxious ... meet Google’s new requirements,” commented Fran Acunzo, CEO of Acara ... education, non-profits, and the business world.” , Back in ...
Breaking Medicine News(10 mins):Health News:Glee star Lauren Potter helps Down Syndrome Association of WI raise awareness, support 2Health News:First of More Than 1,200 Wright Hip Lawsuits Goes to Trial in California Superior Court 2Health News:First of More Than 1,200 Wright Hip Lawsuits Goes to Trial in California Superior Court 3Health News:Tronics Aims to Benefit from Major Growth of Sensors and Related Technologies for Healthcare Applications 2Health News:First ANT FE-C Enabled Fitness Products Enter Market 2Health News:First ANT FE-C Enabled Fitness Products Enter Market 3Health News:Acara Partners Expands Website and Digital Offerings 2
... with Medtronic delivery and glucose sensing leadership INDIANAPOLIS and ... names in diabetes management -Eli Lilly and Company (NYSE: ... MDT ) - today announced a strategic marketing ... with diabetes manage their blood sugar using insulin therapy.Working ...
... and Data Management Providers Expands Area Market RoleSANTA ... a leading provider of digital radiography (DR), ultrasound, ... management software (VIA(R)) for veterinary care, announced it ... West Coast ultrasound representative. Thorn brings strong animal ...
... brain ,sings, could improve our understanding of conditions such ... scientists at Cardiff University have discovered. , Research ... Imaging Centre (CUBRIC) has discovered that a person,s brain ... when a person looks at a visual pattern. ...
... Television Infrastructure to Enable System Turn-On At Grand ... May 19 LodgeNet Healthcare, a division of ... and the leading provider of interactive patient television ... Television System is now serving patients at the ...
... Policy Actions at the Federal Level , ... (PRWEB) ... more than 200 viral hepatitis groups around the world have planned ... support for improvements in prevention, diagnosis, treatment and support for people ...
... May 19 The Quigley Corporation, (Nasdaq: ... www.quigleyco.com , today announced that it has ... the Company,s Quigley Pharma, Inc. wholly-owned subsidiary COO, Dr. ... of documentary evidence of undisclosed payments from Karkus to ...
Cached Medicine News:Health News:Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 2Health News:Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 3Health News:Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 4Health News:Eklin Medical Systems Appoints Juan Thorn as West Coast Ultrasound Sales Representative 2Health News:'Singing brains' offers epilepsy and schizophrenia clues 2Health News:LodgeNet Healthcare Announces Deployment of Interactive Patient Television System in Oklahoma Heart Hospital 2Health News:LodgeNet Healthcare Announces Deployment of Interactive Patient Television System in Oklahoma Heart Hospital 3Health News:National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action 2Health News:National Viral Hepatitis Roundtable Observes World Hepatitis Day and Calls for Increased Federal Action 3Health News:Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation 2Health News:Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation 3Health News:Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation 4Health News:Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation 5
Form: Cream-colored powder Moisture: 10% Ash: 6.5% Gel Strength (1.5%): 550 950 gm/cm 2 Gel pH (1.5%): 6.0 7.5 Gel Point (1.5%): 34 38C Melting Point (1.5%): 84 88C Application: Bacterial ...
... generation of a hypoxic environment for tissue ... surface-type seal where all portions of the ... steel ring clamp for a reliable air-tight ... and bottom provide minimum gas flow resistance ...
... range of miniTHERM incubators is available, ensuring ... solution for their specific requirements. miniTHERM incubators ... compact and extremely space saving. Their size ... It is possible to stack up to ...
... Steri-Cult has been the leading ... volume cell culture for more ... the name that brought leading ... CO 2 sensors,microprocessor control, ...
Medicine Products: